protein purification procedure (detailed in the Materials and Methods section of the main article text) were separated by SDS-PAGE and stained with Coomassie blue. The location of 6xHis-PA3225 is shown with an arrow. "Vector control" refers to whole cell proteins isolated from IPTG-induced E. coli BL21(DE3) carrying pET30a. The "uninduced" and "induced" lanes contain whole cell proteins from E. coli BL21(DE3) pET30a-PA3225 that was either uninduced or induced with IPTG, respectively. "Soluble lysate" refers to soluble proteins following sonication of IPTG-induced E. coli BL21(DE3) pET30a-PA3225 cells. Soluble lysate was incubated with Ni-NTA agarose beads, and a significant portion of 6xHis-PA3225 was captured by the beads given that the flow-through had much less 6xHis-PA3225 than the input lysate.
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FIG S2. The PA3225-PA3228 genes are co-transcribed. RNA from planktonic ΔPA3225 cultures was reverse transcribed to cDNA, which was subsequently used as a template for PCR with primer sets (see Table 2 ) that amplified various regions of the predicted PA3225-PA3228 operon (regions "a" to "d" shown schematically in lower panel). PCR reactions performed with RNA in the absence of reverse transcriptase were included as controls to demonstrate the absence of contaminating genomic DNA.
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FIG S3. PA3225 is upregulated in biofilms.
Deletion of PA3225 resulted in increased expression of the PA3225-PA3228 locus as determined by qPCR using primers that amplified a portion of the PA3225 transcript that was not deleted in the generation of the ΔPA3225 mutant.
Additionally, in wild-type PA14, PA3225 expression in biofilms was 5-fold higher than that in planktonic cells. Data are shown as mean PA3225 expression relative to wild-type planktonic cells + SEM. ** p ≤ 0.01 as determined by two-tailed Student's t-tests.
FIG S4. Drug gradient plate assays demonstrate that the ΔPA3225 mutant has decreased
antibiotic susceptibility compared to wild-type. PA14 and ΔPA3225 were struck on LB agar plates containing a concentration gradient of (A) nalidixic acid (0 to 120 μg/mL), (B) ciprofloxacin (0 to 0.1 μg/mL), (C) norfloxacin (0 to 0.75 μg/mL), and (D) tetracycline (0 to 16 μg/mL). In all cases, the ΔPA3225 mutant had visible growth at a higher antibiotic concentration than the wild-type PA14 strain. 
